Trials / Active Not Recruiting
Active Not RecruitingNCT04075435
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Mclean Hospital · Academic / Other
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).
Conditions
- Alzheimer Disease
- Anxiety
- Agitation,Psychomotor
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | high CBD/low THC sublingual solution | Hemp derived solution to be administered sublingually twice daily. |
Timeline
- Start date
- 2021-01-11
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2019-08-30
- Last updated
- 2026-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04075435. Inclusion in this directory is not an endorsement.